Skip to content

Comparison of 2 Tests to Diagnose Cognitive Dysfunctions in Alcohol Disease

Comparison of 2 Tests for Screening for Cognitive Disorders (MoCA / BEARNI)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04009707
Acronym
MoCA/BEARNI
Enrollment
90
Registered
2019-07-05
Start date
2017-11-02
Completion date
2018-12-31
Last updated
2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder

Keywords

MoCA, BEARNI

Brief summary

The objective of this study is therefore to compare the results obtained with these two screening tests, using as gold standard the results obtained by the battery of neuropsychological reference tests.

Detailed description

Recently, a new screening test for cognitive disorders was specifically developed for patients with UAS: BEARNI (Brief Evaluation of Alcohol-Related Neuropsychological Impairments). Since the BEARNI is presented as the reference test, the investigators have systematically proposed it to hospitalized patients, in combination with the usual check-up. In practice, at admission, patients were therefore given two screening tests, the MoCA and the BEARNI. In the event of an anomaly in at least one of these tests, a battery of confirmatory neuropsychological tests was performed.

Interventions

OTHERMoCA (Montreal Cognitive Assessment) test

the MoCA questionnaire is used to assess cognitive disorders

OTHERBEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test

This questionnaire is used to assess cognitive disorders

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* patients with alcoo use desorder * Patient cared for in the addictology department of the University Hospital of Nîmes

Exclusion criteria

* refusal to use the data

Design outcomes

Primary

MeasureTime frameDescription
sensitivityDay 1 (only 1 time)comparison of the sensitivity of the 2 tests against the gold standard
specificityDay 1 (only 1 time)comparison of the specificity of the 2 tests against the gold standard

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026